Healios Company

Healios aims to commercialize the world’s first pharmaceutical hiPSC derived RPE cell transplantation for treatment of AMD in collaboration with RIKEN, one of the leading research institutes in Japan. The goal of this therapy is to promote the regeneration of retinal function and, consequently, to improve visual function in those affected with retinal degenerative diseases.The significance of the total raised capital fortifies the company’s momentum in the development of therapeutics utilizing the Nobel Prize-winning hiPSC technology and attests its uncompromising commitment to making groundbreaking strides in the field of regenerative medicine.
Technology: Regenerative Medicine
Industry: Biotechnology, Health Care, Science and Engineering
Headquarters: Tokyo, Tokyo, Japan
Founded Date: 2-24
Employees Number: 11-50
Funding Status: IPO
Investors Number: 6
Total Funding: $1.8M
Estimated Revenue: $1M to $10M
Last Funding Date: 2013-10-08
Last Funding Type: Pre-Seed

Visit Website
info@rijapan.jp
Register and Claim Ownership